Double-stranded nucleotide compound for metabolic diseases and use thereof
Through the design and modification of double-stranded nucleotide compounds, small interfering RNA, combined with drug carriers, the DGAT2 gene expression was successfully inhibited, solving the problem of poor efficacy in NAFLD/NASH treatment in the prior art, and achieving efficient and safe targets Towards the therapeutic effect.
Patent Information
- Application Number
- PCT/CN2024/095285
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2024-05-23
- Filing Date
- 2024-05-24
- Publication Date
- 2024-12-05
AI Technical Summary
The prior art is difficult to effectively inhibit the expression of diacylglycerol acyltransferase-2 (DGAT2), resulting in poor therapeutic effects of non-alcoholic fatty liver disease (NAFLD) and non-alcoholic lipohepatitis (NASH), and traditional methods have targeted Sex and security challenges.
A double-stranded nucleotide compound, specifically small interfering RNA (siRNA), was developed. Through specific sequence design and modification, it can effectively inhibit the expression of the DGAT2 gene and combine it with a drug carrier to form a pharmaceutical composition for the treatment of DGAT2-related diseases.
A significant inhibition of DGAT2 mRNA was achieved, significantly improved the clinical symptoms of NAFLD/NASH, with high stability and low off-target effects, and showed excellent target gene inhibition activity, suitable for non-alcoholic fatty liver disease and other metabolic syndromes treatment.
Smart Images

Figure PCTCN2024095285-FTAPPB-I100001 
Figure PCTCN2024095285-FTAPPB-I100002 
Figure PCTCN2024095285-FTAPPB-I100003
Abstract
Description
A double-stranded nucleotide compound for metabolic diseases and its application Technical Field
[0001] The present disclosure relates to the field of genetic engineering technology, and in particular to small interfering RNA expressing diacylglycerol acyltransferase-2 (DGAT-2) and its use in preparing drugs for treating diseases related to DGAT2 expression. Background Art
[0002] RNA interference (RNAi) technology refers to a highly evolutionarily conserved phenomenon in which double-stranded RNA (dsRNA) induces the efficient and specific degradation of homologous mRNAs. RNA molecules inhibit the expression of specific genes by destroying specific mRNAs. Because RNAi can specifically knock out or shut down the expression of specific genes, it has rapidly become one of the most sought-after research tools in gene function research and gene therapy. It has been widely used to explore gene function and treat metabolic and infectious diseases, as well as malignant tumors.
[0003] Non-alcoholic fatty liver disease (NAFLD) is characterized by the accumulation of triglycerides in the liver, which can progress to a severe form called non-alcoholic steatohepatitis (NASH). (Marchesini G, et al. Hepatology 2003;37:917-923)
[0004] Obesity and insulin resistance are common features of patients with NAFLD (Byrne CD and Targher GJ Hepatol 2015 Apr;62(1S):S47-S64). With the increasing prevalence of obesity and type 2 diabetes, the incidence of NAFLD has been increasing, with the latest estimates reaching 25% worldwide, of which approximately 3-5% of the population has NASH. NAFLD is currently the most common chronic liver disease, and NASH is expected to become the leading cause of liver transplantation in the United States within the next decade.
[0005] NAFLD has different characteristics at different stages: simple hepatic steatosis alone, and the more severe NASH, in which steatosis is accompanied by intralobular inflammation and ballooning, as well as hepatocellular degeneration. NASH is a progressive disease that can lead to cirrhosis and hepatocellular carcinoma (Farrell GC and Larter CZ. Hepatology 2006;43:S99-S112; Cohen JC et al., Science 2011;332:1519-1523). The risk of progression to advanced liver disease depends on factors such as the severity of inflammation and fibrosis, as well as the presence of other diseases such as obesity, type 2 diabetes, and high cholesterol.
[0006] Diacylglycerol acyltransferase (DGAT) is an enzyme that plays a key role in triglyceride (TG) synthesis. DGAT catalyzes the final step of TG synthesis by linking sn-1,2-diacylglycerol (DAG) to acyl-CoA.
[0007] DGAT1 and DGAT2 are two isoforms with different roles and tissue expression patterns, but both play an important role in triglyceride synthesis. DGAT1 is mainly found in the small intestine and white adipose tissue (WAT), while DGAT2 is mainly found in the liver and white adipose tissue (WAT) (Cases S, et al. Proc Natl Acad Sci USA 1998; 95, 13018-13023; Cases S, et al. J Biol Chem 2001; 276, 38870-38876). DGAT1 and DGAT2 have different subcellular localizations (Cao J, et al. J Lipid Res 2007; 48: 583-591; Cheng D, et al. J Biol Chem 2008; 283: 29802-29811), subcellular localizations (Stone SJ, et al. J Biol Chem 2004; 279: 11767-11776), and physiological regulatory functions (Meegalla RL, et al. Biochem Biophys Res Commun 2002, 298, 317-323). Inhibition of DGAT2 by antisense oligonucleotide treatment has been shown to improve hepatic steatosis and blood lipid levels in several studies in obese rodent models, and data indicate that these effects are associated with reduced hepatic lipid synthesis (Yu XX, et al. Hepatology 2005; 42: 362-371, Yamaguchi K et al. HEPATOLOGY, Vol. 45, No. 6, 2007 1366-1374). A recent academic paper also reported long-term suppression of DGAT2 mRNA and significant improvement of the fatty liver phenotype (Yenilmez, B et al. Molecular Therapy Vol. 30 No 3 March 2022).
[0008] DGAT2 inhibition may also lead to increased fat oxidation, as DGAT2 ASOs reduce the expression of lipogenic genes: ACC1, mtGPAT, SCD1, and SREBP1, and increase the expression of oxidative / thermogenic genes CPT1 and UCP2 (Yu XX, et al. Hepatology 2005; 42: 362-371)
[0009] These studies suggest that DGAT2 inhibition may be a viable strategy for developing treatments for NAFLD / NASH and other metabolic syndromes. Targeted DGAT2 inhibition may provide therapeutic benefits by lowering triglycerides, improving insulin sensitivity, and reducing hepatic steatosis.
[0010] Small molecule inhibitors and ASOs targeting DGAT2 have reported promising results in reducing hepatic steatosis in clinical trials. siRNA technology has been shown to offer significant advantages over traditional approaches in terms of improved specificity, durability, and safety. Targeting DGAT2 with siRNA has the potential to reduce hepatic steatosis and improve metabolic parameters in patients with NAFLD / NASH and other metabolic disorders.
[0011] Summary of the Invention
[0012] The present invention aims to discover and develop siRNA and its derivatives that can inhibit and / or reduce DGAT2 expression.
[0013] The first aspect of the present invention provides an siRNA comprising a sense strand and an antisense strand, wherein the sense strand and the antisense strand comprise a double-stranded region formed by reverse complementation. In some embodiments of the first aspect of the present invention, at least a portion of the sense strand and at least a portion of the antisense strand are reverse complementary and form a double-stranded region. In some embodiments of the first aspect of the present invention, the length of the double-stranded region is 17 to 22 base pairs. In some embodiments of the first aspect of the present invention, the length of the double-stranded region is 21 base pairs.
[0014] In some embodiments of the first aspect of the present invention, the sense strand of the siRNA comprises a sequence as shown in any one of SEQ ID NOs: 1-96. In some embodiments of the first aspect of the present invention, the sense strand of the siRNA comprises 17 to 22 consecutive bases of a sequence as shown in any one of SEQ ID NOs: 1-96. In some embodiments of the first aspect of the present invention, the sense strand of the siRNA comprises 17, 18, 19, 20, 21 or 22 consecutive bases of a sequence as shown in any one of SEQ ID NOs: 1-96. In some embodiments of the first aspect of the present invention, the sense strand of the siRNA comprises 20 consecutive bases of a sequence as shown in any one of SEQ ID NOs: 1-96.
[0015] In some embodiments of the first aspect of the present invention, the antisense strand of the siRNA comprises a base sequence as shown in any one of SEQ ID NOs: 97-192. In some embodiments of the first aspect of the present invention, the antisense strand of the siRNA comprises 17 to 22 consecutive bases of a sequence as shown in any one of SEQ ID NOs: 97-192 and 194-199. In some embodiments of the first aspect of the present invention, the antisense strand of the siRNA comprises 17, 18, 19, 20, 21 or 22 consecutive bases of a sequence as shown in any one of SEQ ID NOs: 97-192 and 194-199. In some embodiments of the first aspect of the present invention, the antisense strand of the siRNA comprises 20 consecutive bases of a sequence as shown in any one of SEQ ID NOs: 97-192 and 194-199.
[0016] In some embodiments of the first aspect of the present invention, the sense strand contained in the siRNA contains 17 to 22 consecutive bases of a sequence as shown in any one of SEQ ID NOs: 1-96, and the antisense strand contained in the siRNA contains 17 to 22 consecutive bases of a sequence as shown in any one of SEQ ID NOs: 97-192, and at least a portion of the sense strand and at least a portion of the antisense strand are reversely complementary to form a double-stranded region, and the length of the double-stranded region is 17 to 22 base pairs.
[0017] In some embodiments of the first aspect of the present invention, the sense strand of the siRNA comprises 17 to 22 consecutive bases (further 20 consecutive bases) of the sequence as shown in SEQ ID NO: 77 or SEQ ID NO: 201, and the antisense strand comprises 17 to 22 consecutive bases (further 20 consecutive bases) of the sequence as shown in SEQ ID NO: 173; or the sense strand comprises 17 to 22 consecutive bases (further 20 consecutive bases) of the sequence as shown in SEQ ID NO: 17, and the antisense strand comprises 17 to 22 consecutive bases (further 20 consecutive bases) of the sequence as shown in SEQ ID NO: 113; or the sense strand comprises 17 to 22 consecutive bases (further 20 consecutive bases) of the sequence as shown in SEQ ID NO: 80, and the antisense strand comprises 17 to 22 consecutive bases (further 20 consecutive bases) of the sequence as shown in SEQ ID NO: 176.
[0018] In some embodiments, the sense strand of the siRNA comprises a sequence as shown in SEQ ID NO: 77 or SEQ ID NO: 201, and the antisense strand comprises 20 consecutive bases of a sequence as shown in SEQ ID NO: 173, 194, or 195. In some embodiments, the sense strand of the siRNA comprises a sequence as shown in SEQ ID NO: 77, and the antisense strand comprises AAGCAAAUAGUCUAUGGUGU (SEQ ID NO: 194). In some embodiments, the sense strand of the siRNA comprises a sequence as shown in SEQ ID NO: 77, and the antisense strand comprises UAAGCAAAUAGUCUAUGGUGU (SEQ ID NO: 195).
[0019] In some embodiments, the sense strand comprised by the siRNA comprises the sequence as shown in SEQ ID NO: 17, and the antisense strand comprises 20 consecutive bases of the sequence as shown in SEQ ID NO: 113, 196, or 197. In some embodiments, the sense strand comprised by the siRNA comprises the sequence as shown in SEQ ID NO: 17, and the antisense strand comprises UUAAAUAACCCACAGACACC (SEQ ID NO: 196). In some embodiments, the sense strand comprised by the siRNA comprises the sequence as shown in SEQ ID NO: 17, and the antisense strand comprises UUUAAAUAACCCACAGACACC (SEQ ID NO: 197).
[0020] In some embodiments, the sense strand of the siRNA comprises the sequence shown in SEQ ID NO: 80, and the antisense strand comprises 20 consecutive bases of the sequence shown in SEQ ID NO: 176, 198 or 199. In some embodiments, the sense strand of the siRNA comprises the sequence shown in SEQ ID NO: 80, and the antisense strand comprises UGUAUUUCUGGAACUUCUUC (SEQ ID NO: 198). In some embodiments, the sense strand of the siRNA comprises the sequence shown in SEQ ID NO: 80, and the antisense strand comprises UUGUAUUUCUGGAACUUCUUC (SEQ ID NO: 199).
[0021] In some embodiments, the sense strand comprised by the siRNA comprises the sequence as shown in SEQ ID NO: 77 or 201, and the antisense strand comprises 20 consecutive bases of the sequence as shown in SEQ ID NO: 173, 194, or 200. In some embodiments, the sense strand comprised by the siRNA comprises the sequence as shown in SEQ ID NO: 77, and the antisense strand comprises AAGCAAAUAGUCUAUGGUGU (SEQ ID NO: 194). In some embodiments, the sense strand comprised by the siRNA comprises the sequence as shown in SEQ ID NO: 77, and the antisense strand comprises AAAGCAAAUAGUCUAUGGUGU (SEQ ID NO: 200). In some embodiments, the sense strand comprised by the siRNA comprises the sequence as shown in SEQ ID NO: 201, and the antisense strand comprises the sequence as shown in SEQ ID NO: 200.
[0022] In some embodiments of the first aspect of the invention, the sense strand of the siRNA comprises the nucleotide sequence of the sense strand of an siRNA molecule as shown in Table 2, and the antisense strand comprises the nucleotide sequence of the antisense strand of the same siRNA molecule as shown in Table 2. In certain embodiments, the siRNA has one or more modified nucleotides, and the modified nucleotides can be at any suitable position of the sense strand and / or antisense strand of the siRNA. In certain embodiments, the siRNA has one or more modified nucleotides, and the modified nucleotides are at the modified nucleotide positions of the corresponding siRNA molecule in Table 2. In certain embodiments, the siRNA has the same nucleotide sequence as the corresponding siRNA molecule in Table 2, and has the modified nucleotides at the same positions. In certain embodiments, the siRNA has the same nucleotide sequence as the corresponding siRNA molecule in Table 2, and has the same modified nucleotides at the same positions.
[0023] In some embodiments, the siRNA comprises:
[0024] a) a sense strand (5'→3') containing the following nucleotide sequence: ggugucugUfGfGfguuauuuaaa, and an antisense strand (5'→3') containing the following nucleotide sequence: u*Uf*u*AfaAfuaaccCfaCfaGfaCfaCf*c,
[0025] b) a sense strand comprising the following nucleotide sequence: gaagaaguUfCfCfagaaauacaa, and an antisense strand (5'→3') comprising the following nucleotide sequence: u*Uf*g*UfaUfuucugGfaAfcUfuCfuUf*c;
[0026] c) a sense strand comprising the following nucleotide sequence: accacauaGfAfCfuauuugcuua, and an antisense strand (5'→3') comprising the following nucleotide sequence: u*Af*a*GfcAfaauagUfcUfaUfgGfuGf*u;
[0027] d) a sense strand comprising the following nucleotide sequence: accacauaGfAfCfuauuugcuuu, and an antisense strand (5'→3') comprising the following nucleotide sequence: a*Af*a*GfcAfaauagUfcUfaUfgGfuGf*u;
[0028] Wherein, * indicates that two nucleotides are connected by a phosphorothioate bond, lowercase letters (e.g., a, u, g, c) indicate that the ribose of the nucleotide is modified by 2'-methoxy (i.e., 2'-O-methyl), and capital letters A, U, C, G, and T are followed by "f" to indicate that the ribose of the nucleotide is modified by 2'-fluoro.
[0029] In some embodiments, the siRNA further comprises abasic nucleotides at the 3' and / or 5' end of the sense strand or antisense strand, optionally, inverted abasic nucleotides. In some embodiments, the abasic nucleotides or inverted abasic nucleotides are connected to the 3' and / or 5' end of the sense strand or antisense strand through phosphorothioate. In some embodiments, the siRNA further comprises 5' vinylphosphonate (VP) at the 5' end of the antisense strand and is modified. In some embodiments, the VP modification is connected to the 5' end of the antisense strand through phosphorothioate.
[0030] In some embodiments, the siRNA comprises:
[0031] a) a sense strand (5'→3') comprising the following nucleotide sequence: (invAb)*ggugucugUfGfGfguuauuuaaa*(invAb), and an antisense strand (5'→3') comprising the following nucleotide sequence: u*Uf*u*AfaAfuaaccCfaCfaGfaCfaCf*c,
[0032] b) a sense strand comprising the following nucleotide sequence: (invAb)*gaagaaguUfCfCfagaaauacaa, and an antisense strand (5'→3') comprising the following nucleotide sequence: u*Uf*g*UfaUfuucugGfaAfcUfuCfuUf*c or Vpu*Uf*g*UfaUfuucugGfaAfcUfuCfuUf*c;
[0033] c) a sense strand comprising the following nucleotide sequence: (invAb)*acaccauaGfAfCfuauuugcuua, and an antisense strand (5'→3') comprising the following nucleotide sequence: u*Af*a*GfcAfaauagUfcUfaUfgGfuGf*u or Vpu*Af*a*GfcAfaauagUfcUfaUfgGfuGf*u;
[0034] d) a sense strand comprising the following nucleotide sequence: (invAb)*acaccauaGfAfCfuauuugcuuu*(invAb), and an antisense strand (5'→3') comprising the following nucleotide sequence: a*Af*a*GfcAfaauagUfcUfaUfgGfuGf*u;
[0035] Wherein, * indicates that the two nucleotides are connected by a phosphorothioate bond, lowercase letters (e.g., a, u, g, c) indicate that the ribose of the nucleotide is modified by 2'-methoxy (i.e., 2'-O-methyl), uppercase letters A, U, C, G, and T are followed by "f" to indicate that the ribose of the nucleotide is modified by 2'-fluorine, invAb indicates an inverted abasic nucleotide, and VP indicates vinyl phosphonate.
[0036] In some embodiments, the siRNA further comprises a ligand group at the 3' and / or 5' end of the sense strand. Any suitable ligand group can be used. In some embodiments, the siRNA further comprises a ligand group provided herein at the 3' and / or 5' end of the sense strand, such as, but not limited to, L96 or NAG37. In some embodiments, the siRNA further comprises a ligand group provided herein at the 3' end of the sense strand, such as, but not limited to, L96 or NAG37.
[0037] In some embodiments of the first aspect of the present invention, the siRNA is selected from dS004-dS099, as shown in Table 2. In some embodiments of the first aspect of the present invention, the siRNA is selected from dS004, dS005, dS006, dS007, dS008, dS009, dS010, dS011, dS012, dS013, dS014, dS015, dS016, dS017, dS018, dS019, dS020, dS021, dS022, dS023, dS024, dS025, dS026, dS0 27. dS028, dS029, dS030, dS031, dS032, dS033, dS034, dS035, dS036, dS037, dS038, dS039, dS040, d S041, dS042, dS043, dS044, dS045, dS046, dS047, dS048, dS049, dS050, dS051, dS052, dS053, dS054, dS055, dS056, dS057, dS058, dS059, dS060, dS061, dS062, dS063, dS064, dS065, dS066, dS067, dS06 8. dS069, dS070, dS071, dS072, dS073, dS074, dS075, dS076, dS077, dS078, dS079, dS080, dS081, dS0 82, dS083, dS084, dS085, dS086, dS087, dS088, dS089, dS090, dS091, dS092, dS093, dS094, dS095, dS096, dS097, dS098, dS099, dS279, dS280, dS281, dS282, dS283, dS284, dS285, dS286, dS287, or dS288.
[0038] In the second aspect of the present invention, a siRNA conjugate is provided, which comprises the siRNA as described in the scheme of the first aspect of the present invention and a ligand group, wherein the ligand group is conjugated to the siRNA, and the ligand group comprises 1, 2, 3 or 4 GalNAc groups, and the number of the ligand groups is 1, 2, 3, 4, 5, 6 or 7.
[0039] In some embodiments of the second aspect of the present invention, the number of the ligand group is one.
[0040] In some embodiments of the second aspect of the present invention, the ligand group comprises three GalNAc groups. In some embodiments of the second aspect of the present invention, the ligand group comprises the structure of L96. In some embodiments of the second aspect of the present invention, the ligand group comprises the structure of NAG37.
[0041] In some embodiments of the second aspect of the present invention, the siRNA conjugate is selected from dS301, dS302, dS303, dS304, dS305, dS306, dS307, dS316, dS319 or dS324.
[0042] The third aspect of the present invention provides a pharmaceutical composition, which comprises the siRNA as described in the scheme of the first aspect of the present invention or the siRNA conjugate as described in the scheme of the second aspect of the present invention and a pharmaceutically acceptable carrier.
[0043] In a fourth aspect, the present invention provides use of the siRNA described in the first aspect of the present invention, the siRNA conjugate described in the second aspect of the present invention, or the pharmaceutical composition described in the third aspect of the present invention in the preparation of a drug for treating diseases related to DGAT2 expression.
[0044] In some solutions of the fourth aspect of the present invention, the disease associated with DGAT2 expression is a lipid metabolism disease.
[0045] In some schemes of the fourth aspect of the present invention, the disease associated with DGAT2 expression is non-alcoholic fatty liver disease and non-alcoholic steatohepatitis.
[0046] In a fifth aspect, the present invention provides a method for treating diseases and / or conditions associated with DGAT2 expression, wherein the method comprises administering a therapeutically effective amount of the above-mentioned siRNA, siRNA conjugate and / or pharmaceutical composition to a subject in need thereof.
[0047] In some solutions of the fifth aspect of the present invention, the disease associated with DGAT2 expression is a lipid metabolism disease.
[0048] In some solutions of the fifth aspect of the present invention, the disease associated with DGAT2 expression is non-alcoholic fatty liver disease and non-alcoholic steatohepatitis.
[0049] In a sixth aspect, the present invention provides a method for inhibiting the expression of the DGAT2 gene in a cell, comprising contacting the cell with an effective amount of the above-mentioned siRNA, siRNA conjugate and / or pharmaceutical composition, thereby inhibiting the expression of the DGAT2 gene in the cell.
[0050] As described above, in addition to their administration, the siRNAs and / or siRNA conjugates characterized herein can be administered in combination with other known agents that effectively inhibit DGAT2 expression. In any case, the administering physician can adjust the amount and timing of siRNA and / or siRNA conjugate administration based on the results observed using standard efficacy measurements known in the art or described herein.
[0051] The present invention provides the following sequences, which are written and read in the 5' to 3' direction:
[0052] Table 1.1 Sequences involved in the present invention
[0053] Table 1.2 Sequences involved in the present invention
[0054] The present invention provides siRNAs and siRNA conjugates as shown in the table below. The following sequences are written and read in the 5' to 3' direction. The abbreviations or abbreviations used in this table are as follows: (invAb) is an inverted abasic ribonucleic acid, * indicates that the two nucleotides are connected by a phosphorothioate bond, lowercase letters (e.g., a, u, g, c) indicate that the nucleotide is modified with a 2'-methoxy (i.e., 2'-O-methyl) group, uppercase letters A, U, C, G, and T are followed by an "f" to indicate that the nucleotide is modified with a 2'-fluoro group, VP is vinylphosphonate, and L96 represents a ligand group with the following structure:
[0055] NAG37 represents a ligand group of the following structure:
[0056] Table 2 siRNAs involved in the present invention Beneficial effects
[0057] The siRNA, siRNA conjugate and pharmaceutical composition provided by the present invention have good stability, high DGAT2 mRNA inhibitory activity, low off-target effect, and / or can significantly treat diseases and / or disorders related to DGAT2 expression.
[0058] The siRNA, siRNA conjugates and pharmaceutical compositions provided by the present invention show excellent target gene inhibitory activity in in vitro experiments. In some embodiments, the siRNA, siRNA conjugates and pharmaceutical compositions provided by the present invention show an inhibitory activity of greater than or equal to 80%, 85%, 90% or 95% on the target gene at a concentration of 100nM in in vitro experiments. In some embodiments, the siRNA or siRNA conjugates provided by the present invention show an inhibitory activity of greater than or equal to 50%, 60%, 70%, 80%, 90%, 91% or 92% on the target gene at a concentration of 10nM in in vitro experiments. In some embodiments, the siRNA or siRNA conjugates provided by the present invention show an inhibitory activity of greater than or equal to 40%, 50%, 60%, 70%, 80% or 90% on the target gene at a concentration of 0.5nM in in vitro experiments. In some embodiments, the siRNA or siRNA conjugates provided by the present invention show an IC 50 In some embodiments, the siRNA or siRNA conjugates provided by the present invention show the inhibitory activity to the target gene in vitro experiments, which is the reduction of the expression level of the target gene mRNA measured by qPCR. In some embodiments, the siRNA or siRNA conjugates provided by the present invention show the inhibitory activity to the target gene in vitro experiments, which is measured in human liver cancer cells (such as Huh7 cells). In some embodiments, the siRNA or siRNA conjugates provided by the present invention show the inhibitory activity to the target gene in vitro experiments, which is measured in human liver cells (such as primary human liver cells (PHH)). In some embodiments, the siRNA or siRNA conjugate provided by the present invention shows inhibitory activity against the target gene in an in vitro experiment, which is measured by the method described in Example 2 or 3. In some embodiments, the target gene is DGAT2.
[0059] The siRNA, siRNA conjugates and pharmaceutical compositions provided by the present invention show excellent target gene inhibition activity in in vivo experiments. In some embodiments, the target gene is DGAT2.
[0060] In some embodiments, the siRNA, siRNA conjugates and pharmaceutical compositions provided by the present invention show an average inhibition rate of greater than or equal to 10%, 20%, 30%, 40%, 50%, 60%, 70% or 80% of the target gene in in vivo experiments after 7 days of administration. In some embodiments, the siRNA, siRNA conjugates and pharmaceutical compositions provided by the present invention show an average inhibition rate of greater than or equal to 10%, 20%, 30%, 40%, 50%, 60% or 65% of the target gene in in vivo experiments after 28 days of administration. In some embodiments, the siRNA, siRNA conjugates and pharmaceutical compositions provided by the present invention show inhibitory activity against the target gene in in vivo experiments, which is measured by reducing the expression level of the target gene mRNA in the liver of wild-type mice as measured by qPCR. In some embodiments, the siRNA, siRNA conjugates and pharmaceutical compositions provided by the present invention show inhibitory activity against the target gene in in vivo experiments, which is measured by the method described in Example 4 or 6.
[0061] In some embodiments, the siRNA, siRNA conjugates and pharmaceutical compositions provided by the present invention show an average inhibition rate of greater than or equal to 50%, 60%, 70%, 80%, 90%, 95% or 97% of the target gene in in vivo experiments after 15 days of administration. In some embodiments, the siRNA, siRNA conjugates and pharmaceutical compositions provided by the present invention show inhibitory activity on the target gene in in vivo experiments, which is measured by qPCR to reduce the expression level of the target gene mRNA in the liver of a mouse model of high-pressure tail vein injection of a human target gene plasmid. In some embodiments, the siRNA, siRNA conjugates and pharmaceutical compositions provided by the present invention show inhibitory activity on the target gene in in vivo experiments, which is measured by the methods described in Examples 5, 7 or 8.
[0062] In some embodiments, the siRNAs, siRNA conjugates, and pharmaceutical compositions provided herein demonstrate in vivo improvements in Western diet-induced non-alcoholic steatohepatitis in human target gene mice. In some embodiments, the siRNAs, siRNA conjugates, and pharmaceutical compositions provided herein demonstrate in vivo improvements in Western diet-induced non-alcoholic steatohepatitis in human DGAT2 mice, as measured by the methods described in Example 9.
[0063] In some embodiments, the siRNA, siRNA conjugates and pharmaceutical compositions provided by the present invention show an average inhibition rate of greater than or equal to 50%, 60%, 70%, 80%, 90% or 95% of the target gene in in vivo experiments at 29 days of administration. In some embodiments, the siRNA, siRNA conjugates and pharmaceutical compositions provided by the present invention show an average inhibition rate of greater than or equal to 60%, 70%, 80%, 90% or 95% of the target gene in in vivo experiments at 57 days of administration. In some embodiments, the siRNA, siRNA conjugates and pharmaceutical compositions provided by the present invention show inhibitory activity against the target gene in in vivo experiments, which is measured by qPCR to reduce the expression level of the target gene mRNA in the liver of eluted cynomolgus monkeys. In some embodiments, the siRNA, siRNA conjugates and pharmaceutical compositions provided by the present invention show inhibitory activity against the target gene in in vivo experiments, which is measured by the method described in Example 10 or 11. The siRNA, siRNA conjugates and pharmaceutical compositions provided by the present invention do not show obvious off-target effects. An off-target effect can be, for example, inhibition of normal gene expression of a non-target gene. An off-target effect is considered insignificant if the binding / inhibition of off-target gene expression is less than 50%, 40%, 30%, 20%, or 10% compared to the on-target effect.
[0064] definition
[0065] Unless otherwise specified, the following terms and phrases used herein are intended to have the following meanings. The absence of a specific definition for a term or phrase should not be construed as indefinite or unclear, but rather should be understood in accordance with its ordinary meaning. When a trade name appears herein, it is intended to refer to the corresponding commercial product or active ingredient.
[0066] In the present invention, "optional" or "optionally" means that the event or situation described thereafter may or may not occur, and the description includes instances where the event or situation occurs and instances where it does not occur. For example, "optionally substituted" "alkyl" includes "alkyl" and "substituted alkyl" as defined below. It will be understood by those skilled in the art that, for any group containing one or more substituents, these groups are not intended to introduce any substitution or substitution pattern that is sterically impractical, synthetically unfeasible, and / or inherently unstable.
[0067] In the present invention, "subject" refers to any animal, such as a mammal or marsupial. The subject of the present invention includes, but is not limited to, humans, non-human primates (e.g., rhesus monkeys or other types of macaques), mice, pigs, horses, cattle, rats, or any kind of poultry.
[0068] As used herein, "treatment" refers to an approach for obtaining beneficial or desired results, including but not limited to a therapeutic benefit. "Therapeutic benefit" means eradication or amelioration of the underlying disorder being treated. Furthermore, a therapeutic benefit is achieved by eradication or amelioration of one or more physiological symptoms associated with the underlying disorder, such that an improvement is observed in the subject, even though the subject may still be afflicted with the underlying disorder.
[0069] In the present invention, siRNA or siRNA conjugates can be used to treat diseases. In some embodiments of the present invention, the disease is a drug for a disease associated with DGAT2 expression. In some embodiments of the present invention, the disease associated with DGAT2 expression is a lipid metabolism disease. In some embodiments of the present invention, the disease associated with DGAT2 expression is non-alcoholic fatty liver disease and non-alcoholic steatohepatitis.
[0070] In the present invention, "small interfering RNA", "siRNA", "RNAi" or "iRNA agent" are used interchangeably to refer to a double-stranded ribonucleic acid molecule that is long enough to trigger an interferon response and enter RISC (RNA-induced silencing complex), and short enough so that it does not induce a harmful interferon response in human cells (for example, an siRNA agent or its cleavage product can down-regulate a target gene by, for example, inducing RNAi about a target RNA, wherein the target may include an endogenous or pathogenic target RNA). In some embodiments of the present invention, the siRNA is at least partially complementary to a coding sequence in a target gene expressed in a cell. In some embodiments of the present invention, after the siRNA is delivered to a cell expressing the gene, the siRNA is able to inhibit or block the expression of the gene in vitro or in vivo. Typically, the siRNA comprises a double-stranded region of less than 60, 50, 40 or 30 complementary base pairs; preferably, it comprises a double-stranded region of 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21 or 22 complementary base pairs. In some embodiments of the present invention, the sense strand and antisense strand of the siRNA are independently 15-30 nucleotides in length, and the length of the complementary double-stranded region formed is 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21 or 22 base pairs. In some embodiments of the present invention, the sense strand and antisense strand of the siRNA are fully complementary and paired, and have a length of 15-30 base pairs. In some embodiments of the present invention, the sense strand and antisense strand of the siRNA are fully complementary and paired, and have a length of 17, 18, 19, 20, 21 or 22 base pairs.
[0071] In the present invention, when an siRNA "targets" a target gene (or a specified segment of a target gene), it means that the antisense strand of the siRNA is at least partially complementary to at least a portion of the RNA transcribed from the target gene (or a specified segment thereof). In some embodiments of the present invention, the siRNA provided herein targets the diacylglycerol acyltransferase 2 (Acyl CoA: Diacylglycerol Acyltransferase 2, DGAT2) gene. In some embodiments of the present invention, the antisense strand of the siRNA provided herein is at least partially complementary to the targeted segment of the RNA transcribed from the DGAT2 gene. In some embodiments of the present invention, the antisense strand of the siRNA provided herein is fully complementary to the targeted segment of the RNA transcribed from the DGAT2 gene.
[0072] The position of the targeted fragment of the DGAT2 gene targeted by the antisense strand of the siRNA provided by the present invention can be based on the position in the DGAT2 gene transcript. In some embodiments of the present invention, the accession number of the DGAT2 gene transcript in the NCBI data is NM_032564.5. In some embodiments of the present invention, the sequence of the DGAT2 gene transcript is as shown in SEQ ID NO:193. In some embodiments of the present invention, the siRNA provided by the present invention targets any continuous 17 to 22 (e.g., 20 or 21) nucleotide sequences in positions 450-600 of SEQ ID NO:193. In some embodiments of the present invention, the siRNA provided by the present invention targets any continuous 17 to 22 (e.g., 20 or 21) nucleotide sequences in positions 475-512 or 529-562 of SEQ ID NO:193. In some embodiments of the present invention, the siRNA provided by the present invention targets any continuous 17 to 22 (e.g., 20 or 21) nucleotide sequences in positions 489-509 of SEQ ID NO:193.
[0073] In some embodiments of the present invention, the siRNA provided by the present invention targets any consecutive 17 to 22 (e.g., 20 or 21) nucleotide sequences in positions 600-700 of SEQ ID NO: 193. In some embodiments of the present invention, the siRNA provided by the present invention targets any consecutive 17 to 22 (e.g., 20 or 21) nucleotide sequences in positions 614-639 or 660-696 of SEQ ID NO: 193.
[0074] In some embodiments of the present invention, the siRNA provided by the present invention targets any consecutive 17 to 22 (e.g., 20 or 21) nucleotide sequences in positions 700-800 of SEQ ID NO: 193. In some embodiments of the present invention, the siRNA provided by the present invention targets any consecutive 17 to 22 (e.g., 20 or 21) nucleotide sequences in positions 715-768 of SEQ ID NO: 193.
[0075] In some embodiments of the present invention, the siRNA provided by the present invention targets any consecutive 17 to 22 (e.g., 20 or 21) nucleotide sequences in positions 800-1200 of SEQ ID NO: 193. In some embodiments of the present invention, the siRNA provided by the present invention targets any consecutive 17 to 22 (e.g., 20 or 21) nucleotide sequences in positions 832-1002, 1042-1083, or 1102-1155 of SEQ ID NO: 193. In some embodiments of the present invention, the siRNA provided by the present invention targets any consecutive 17 to 22 (e.g., 20 or 21) nucleotide sequences in positions 870-889, 870-890, 1114-1133, or 1114-1134 of SEQ ID NO: 193. In some embodiments of the present invention, the siRNA provided by the present invention targets positions 870-889, 870-890, 1114-1133 or 1114-1134 of SEQ ID NO:193.
[0076] In some embodiments of the present invention, the siRNA provided by the present invention targets any consecutive 17 to 22 (e.g., 20 or 21) nucleotide sequences in positions 1400-1650 of SEQ ID NO: 193. In some embodiments of the present invention, the siRNA provided by the present invention targets any consecutive 17 to 22 (e.g., 20 or 21) nucleotide sequences in positions 1450-1466, 1450-1488, 1491-1547, or 1576-1607 of SEQ ID NO: 193. In some embodiments of the present invention, the siRNA provided by the present invention targets any consecutive 17 to 22 (e.g., 20 or 21) nucleotide sequences in positions 1450-1466, 1450-1488, 1491-1547, or 1576-1607 of SEQ ID NO: 193. A consecutive 17 to 22 (e.g., 20 or 21) nucleotide sequence in positions 1450-1470, 1451-1471, 1452-1472, 1453-1473, 1454-1474, 1455-1475, 1456-1476, 1457-1477, 1458-1478, 1459-1479, 1460-1480, 1461-1481, 1462-1482, 1463-1483, 1464-1484, 1465-1485, 1466-1486, 1467-1487, 1468-1488, 1469-1489, or 1470-1490 of NO: 193. In some embodiments of the invention, the siRNA provided by the invention targets positions 1450-1470, 1451-1471, 1452-1472, 1453-1473, 1454-1474, 1455-1475, 1456-1476, 1457-1477, 1458-1478, 1459-1478, 1459-1479, 1460-1480, 1461-1481, 1462-1482, 1463-1483, 1464-1484, 1465-1485, 1466-1486, 1467-1487, 1468-1488, 1469-1489, or 1470-1490 of SEQ ID NO: 193.
[0077] In some embodiments of the present invention, the siRNA provided by the present invention targets any consecutive 17 to 22 (e.g., 20 or 21) nucleotide sequences in positions 1700-1900 of SEQ ID NO: 193. In some embodiments of the present invention, the siRNA provided by the present invention targets any consecutive 17 to 22 (e.g., 20 or 21) nucleotide sequences in positions 1750-1840 of SEQ ID NO: 193.
[0078] In some embodiments of the present invention, the siRNA provided by the present invention targets any consecutive 17 to 22 (e.g., 20 or 21) nucleotide sequences in positions 2000-2100 of SEQ ID NO: 193. In some embodiments of the present invention, the siRNA provided by the present invention targets any consecutive 17 to 22 (e.g., 20 or 21) nucleotide sequences in positions 2045-2089 of SEQ ID NO: 193.
[0079] In some embodiments of the present invention, the siRNA provided by the present invention targets any continuous 17 to 22 (e.g., 20 or 21) nucleotide sequences in positions 2200-2400 of SEQ ID NO: 193. In some embodiments of the present invention, the siRNA provided by the present invention targets any continuous 17 to 22 (e.g., 20 or 21) nucleotide sequences in positions 2209-2273 or 2326-2376 of SEQ ID NO: 193. In the present invention, "inhibition" refers to when a given gene is expressed, when compared to cells, cell groups or tissues that have not been treated in this way, when the cells, cell groups or tissues are treated with the siRNA, siRNA conjugates and pharmaceutical compositions of the present invention, gene expression is reduced. "Inhibition," "reduction," "silencing," "downregulation," "inhibition" and other similar terms described herein are used interchangeably and include any level of inhibition. Preferably, inhibition includes statistically significant inhibition or clinically significant inhibition.
[0080] In the present invention, "conjugation" refers to the connection between two or more chemical moieties, each of which has a specific function, in a covalently linked manner; accordingly, "conjugate" refers to a compound formed by covalently linking the chemical moieties. Furthermore, "siRNA conjugate" refers to a compound formed by covalently linking one or more chemical moieties (such as ligand groups) with specific functions to siRNA. In this article, the siRNA conjugate of the present invention is sometimes referred to as "conjugate", which should be understood as the full name of the siRNA conjugate according to the context. In some embodiments of the present invention, the ligand group can be connected to the phosphate group of any nucleotide of the siRNA (including the covalent connection of the ligand group to the atom at the 3' or 5' position of the nucleotide through a phosphodiester bond), the 2'-hydroxyl group, the 5'-hydroxyl group or the base. In some embodiments of the present invention, the ligand group can also be connected to the 3'-hydroxyl group, in which case the nucleotides are connected using a 2'-5' phosphodiester bond.
[0081] In the present invention, "ligand group" refers to a pharmaceutically acceptable scaffold group and at least one targeting group, and the siRNA, the scaffold group and the targeting group are connected in sequence, i.e., "siRNA-scaffold group-targeting group". In some embodiments, the targeting groups are 2-4. The siRNA molecule can be non-covalently or covalently conjugated to the ligand group, for example, it can be covalently conjugated to the ligand group. The conjugation site of the siRNA and the ligand group can be at the 3' end or 5' end of the siRNA sense strand, or in the internal sequence of the siRNA. In some embodiments, the conjugation site of the siRNA and the ligand group is at the 3' end or 5' end of the siRNA sense strand. In some embodiments, the conjugation site of the siRNA and the ligand group is at the 5' end of the siRNA sense strand. In some embodiments, the conjugation site of the siRNA and the ligand group is at the 3' end of the siRNA sense strand.
[0082] In the present invention, "targeting group" refers to a targeting agent for cells or tissues of an animal or human body, such as a lectin, glycoprotein, lipid or protein (e.g., antibody) that binds to a specific cell type, such as renal cells. The targeting group can be thyrotropin, melanocyte stimulating hormone, lectin, glycoprotein, surfactant protein A, mucin carbohydrate, multivalent lactose, multivalent galactose, N-acetyl-galactosamine (i.e., GalNAc), N-acetyl-glucosamine multivalent mannose, multivalent fucose, glycosylated polyamino acids, multivalent galactose, transferrin, bisphosphonates, polyglutamic acid, polyaspartic acid, lipid, cholesterol, steroid, bile acid, folic acid, vitamin B12, biotin, RGD peptide, RGD peptide mimetic or aptamer.
[0083] In the present invention, a "scaffold group" refers to a structure that connects two parts of a compound, typically including a direct bond or an atom such as oxygen or sulfur, a unit such as -NR-, -C(=O)-, -C(=O)NH-, -S(=O)-, -SO2-, -SO2NH-, or an atom chain such as substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, arylalkyl, arylalkenyl, arylalkynyl, heteroarylalkyl, heteroarylalkenyl, heteroarylalkynyl, heterocycloalkyl, heterocycloalkenyl, heterocycloalkynyl, aryl, heteroaryl, heterocyclo, cycloalkyl, cycloalkenyl, alkylarylalkyl, alkylarylalkenyl, alkylarylalkynyl, alkenylarylalkyl, alkenylarylalkenyl, alkenylarylalkynyl, alkynylarylalkyl, alkynylarylalkenyl, alkynylarylalkynyl, alkylheteroarylalkyl, alkylheteroaryl wherein one or more methylene radicals may be interrupted or terminated by —O—, —S—, —S(═O)—, —SO—, —N(R)—, —C(═O)—, a cleavable linking group, a substituted or unsubstituted aryl, a substituted or unsubstituted heteroaryl, or a substituted or unsubstituted heterocyclyl; and wherein R is hydrogen, acyl, aliphatic, or substituted aliphatic. The scaffold group can be a divalent, trivalent, tetravalent, pentavalent, hexavalent or more valent group. The scaffold group contains 0, 1, 2 or 3 branch points. In some embodiments of the present invention, the branch point is C, CH, -CH2-, N, -NH-, -O-, -S-, -C(=O)-. In some embodiments of the present invention, the scaffold group is tetravalent, the scaffold group has 1 branch point; further, the scaffold group is In some embodiments of the present invention, the scaffold group is divalent and has 0 branch points; further, the scaffold group is
[0084] In some embodiments of the present invention, the ligand group is [NAG37], and the siRNA conjugate has the structure shown below:
[0085] In some embodiments of the present invention, the ligand group is [L96], and the siRNA conjugate has the structure shown below:
[0086] In the present invention, "complementary" or "reverse complementary" are used interchangeably and refer to a structural relationship between two nucleotides (e.g., on two opposing nucleic acid chains or on opposing regions of a single nucleic acid chain) that allows the two nucleotides to form base pairs with each other (e.g., a purine nucleotide of a nucleic acid that is complementary to a pyrimidine nucleotide of an opposing nucleic acid can form base pairs together by forming hydrogen bonds with each other). In some embodiments of the present invention, complementary nucleotides can form base pairs in a Watson-Crick manner or in any other manner that allows the formation of a stable duplex. In some embodiments of the present invention, two nucleic acid chains may have multiple double-stranded regions that form complementarity. In some embodiments of the present invention, in DNA, adenine (A) always pairs with thymine (T), in RNA, adenine (A) pairs with uracil (U); and guanine (G) always pairs with cytosine (C).
[0087] In the present invention, "mismatch" refers to the situation in which the bases at corresponding positions in a double-stranded nucleic acid molecule are not paired in a complementary manner.
[0088] In the present invention, all chains / sequences are written and read in the 5' to 3' direction.
[0089] In the present invention, siRNA can include one or more modified nucleotides. In some embodiments, the sense strand of siRNA can include one or more modified nucleotides. In the present invention, the sense strand of siRNA can include 1 to 21, 1 to 20, 1 to 19, 1 to 18, 1 to 17, 1 to 16, 1 to 15, 1 to 14, 1 to 13, 1 to 12, 1 to 11, 1 to 10, 1 to 9, 1 to 8, 1 to 7, 1 to 6, 1 to 5, 1 to 4, 1 to 3 or 1 to 2 modified nucleotides. In some embodiments, the sense strand of siRNA can include 21, 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2 or 1 modified nucleotides. In some aspects, the sense strand of the siRNA can include 20 to 21, 19 to 21, 18 to 21, 17 to 21, 16 to 21, 15 to 21, 14 to 21, 13 to 21, 12 to 21, 11 to 21, 10 to 21, 9 to 21, 8 to 21, 7 to 21, 6 to 21, 5 to 21, 4 to 21, 3 to 21, 2 to 21, or 1 to 21 modified nucleotides.
[0090] In some embodiments, the antisense strand of the siRNA may include one or more modified nucleotides. In the present invention, the antisense strand of the siRNA may include 1 to 21, 1 to 20, 1 to 19, 1 to 18, 1 to 17, 1 to 16, 1 to 15, 1 to 14, 1 to 13, 1 to 12, 1 to 11, 1 to 10, 1 to 9, 1 to 8, 1 to 7, 1 to 6, 1 to 5, 1 to 4, 1 to 3 or 1 to 2 modified nucleotides. In some embodiments, the antisense strand of the siRNA may include 21, 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2 or 1 modified nucleotides. In some aspects, the antisense strand of the siRNA can include 20 to 21, 19 to 21, 18 to 21, 17 to 21, 16 to 21, 15 to 21, 14 to 21, 13 to 21, 12 to 21, 11 to 21, 10 to 21, 9 to 21, 8 to 21, 7 to 21, 6 to 21, 5 to 21, 4 to 21, 3 to 21, 2 to 21, or 1 to 21 modified nucleotides.
[0091] In some embodiments, the sense strand of siRNA includes 21 modified nucleotides, and the antisense strand includes 21 modified nucleotides. In some embodiments, the sense strand of siRNA includes 18 modified nucleotides, and the antisense strand includes 13 modified nucleotides. In some embodiments, the sense strand of siRNA includes 18 modified nucleotides, and the antisense strand includes 15 modified nucleotides. In some embodiments, the sense strand of siRNA includes 21 modified nucleotides, and the antisense strand includes 21 modified nucleotides, and both the sense strand and the antisense strand do not include natural nucleotides.
[0092] In the present invention, "G," "C," "A," "T," and "U" refer to nucleotides containing guanine, cytosine, adenine, thymine, and uracil as bases. In the present invention, the presence of "d" before A, U, C, G, and T indicates 2'-deoxyribonucleic acid, while the absence of "d" indicates ribonucleic acid. For example, dA represents deoxyadenine, dU represents deoxyuracil, dC represents deoxycytosine, dG represents deoxyguanine, and dT represents deoxythymine. In the present invention, the presence of "f" after A, U, C, G, and T indicates that the nucleotide is modified with 2'-fluorine. For example, Af represents 2'-fluoroadenine, Uf represents 2'-fluorouracil, Cf represents 2'-fluorocytosine, Gf represents 2'-fluoroguanine, and Tf represents 2'-fluorothymine. Lowercase letters (e.g., a, u, g, c) indicate that the nucleotide is modified with a 2'-methoxy group (i.e., 2'-O-methyl), for example, a is 2'-methoxyadenine, u is 2'-methoxyuracil, c is 2'-methoxycytosine, and g is 2'-methoxyguanine. In the present invention, the * between A, U, C, G, T, etc. indicates that the two nucleotides are connected by a phosphorothioate bond. For example, "A*dU g A Uf G" represents the sequence AUGAUG, starting from the 5' end, where the nucleotides at positions 1 and 2 are connected by a phosphorothioate diester bond, the nucleotide at position 2 is deoxyribonucleic acid, the nucleotide at position 3 is modified with a 2'-methoxy group, and the nucleotide at position 5 is modified with a 2'-fluoro group.
[0093] In some embodiments, the sense strand of the siRNA provided herein has 21 nucleotides, of which 18 are 2'-methoxy-modified nucleotides and 3 are 2'-fluoro-modified nucleotides; and the antisense strand has 21 nucleotides, of which 13 are 2'-methoxy-modified nucleotides and 8 are 2'-fluoro-modified nucleotides. In some embodiments, the sense strand of the siRNA provided by the present invention has 21 nucleotides, and the 1st to 8th and 12th to 21st nucleotides at the 5' end of the sense strand are 2'-methoxy-modified nucleotides, and the 9th to 11th nucleotides are 2'-fluorine-modified nucleotides; and / or the antisense strand of the siRNA provided by the present invention has 21 nucleotides, and the 1st, 3rd, 5th, 7th to 11th, 13th, 15th, 17th, 19th and 21st nucleotides at the 5' end of the antisense strand are 2'-methoxy-modified nucleotides, and the 2nd, 4th, 6th, 12th, 14th, 16th, 18th and 20th nucleotides are 2'-fluorine-modified nucleotides.
[0094] In the present invention, siRNA may include abasic nucleotides. As used herein, the term "abasic" refers to a lack of bases or a portion having other chemical groups replacing 1' bases. In some embodiments, abasic nucleotides may be inverted abasic nucleotides. In some embodiments, the 3' end and / or 5' end of the sense strand of siRNA include abasic nucleotides (e.g., inverted abasic nucleotides). In some embodiments, the 3' end and 5' end of the sense strand of siRNA include inverted abasic nucleotides. In some embodiments, the 5' end of the sense strand of siRNA includes inverted abasic nucleotides.
[0095] In the present invention, siRNA can include one or more modified internucleoside linkages (including the connection between siRNA and the ligand group, and the connection with the abasic nucleotide at the 3' end and / or the 5' end). In some embodiments, the modified internucleoside linkage includes a modified phosphate group, such as a thiophosphate, a selenophosphate, a borane phosphate, a hydrogen phosphonate, a phosphoramidate, an alkyl or aryl phosphonate, or a dithiophosphate. In some embodiments, siRNA can include one or more phosphorothioate-modified internucleoside linkages (including the connection between siRNA and the ligand group, and the connection with the abasic nucleotide at the 3' end and / or the 5' end).
[0096] In some embodiments, the sense strand of siRNA includes phosphorothioate-modified internucleoside linkages (including the connection between siRNA and the ligand group, and the connection with the abasic nucleotide at the 3' end and / or 5' end). In some embodiments, the sense strand of siRNA is phosphorothioate at the 3' end and the 5' end and the connection with the inverted abasic nucleotide, and other internucleoside linkages (including the connection between siRNA and the ligand group) are phosphodiester. In some embodiments, the sense strand of siRNA is phosphorothioate at the 3' end and the 5' end and the connection with the inverted abasic nucleotide and the 3' end and the connection between the inverted abasic nucleotide and the ligand group, and other internucleoside linkages are phosphodiester. In some embodiments, the sense strand of siRNA is phosphorothioate at the 5' end and the connection with the inverted abasic nucleotide, and other internucleoside linkages (including the connection between siRNA and the ligand group) are phosphodiester.
[0097] In some embodiments, the antisense strand of the siRNA comprises phosphorothioate-modified internucleoside linkages. In some embodiments, the linkages between the first and second, second and third, third and fourth, and 20th and 21st nucleotides at the 5' end of the antisense strand of the siRNA are phosphorothioate, and all other internucleoside linkages are phosphodiester.
[0098] In the present invention, siRNA may include a 5'-terminal phosphate or phosphate analog modification. 5'-phosphate modifications include those that are compatible with RISC-mediated gene silencing. Suitable modifications include: 5'-monophosphate ((HO)2(O)P—O-5'); 5'-diphosphate ((HO)2(O)P—O—P(HO)(O)—O-5'); 5'-triphosphate ((HO)2(O)P—O—(HO)(O)P—O—P(HO)(O)—O-5'); 5'-guanosine cap (7-methylated or unmethylated) (7m-GO-5'-(HO)(O)P—O—(HO)(O)P—O—P(HO)(O)—O-5'); 5'-adenosine cap (Appp), and any modified or unmodified nucleotide cap structure (N—O-5'-(HO)(O)P—O—(HO)(O)P—O—P(HO)(O)—O-5'); 5'-monothioate (phosphorothioate; (HO)2(S) P—O-5'); 5'-monodithioic acid esters (phosphorodithioate; (HO)(HS)(S)P—O-5'), 5'-thiophosphate ((HO)2(O)P—S-5'); any combination of monophosphates, diphosphates, and triphosphates with additional oxygen / sulfur substitutions (e.g., 5'-α-thiotriphosphate, 5'-γ-thiotriphosphate, etc.), 5'-phosphoramidates ((HO)2(O)P—NH-5', (HO)(NH2)(O)P—O-5'), 5'-alkylphosphonates (R = alkyl = methyl, ethyl, isopropyl, propyl, etc., e.g., RP(OH)(O)—O-5'-, (OH)2(O)P-5'-CH2-), 5'vinylphosphonates, 5'-alkyletherphosphonates (R = alkylether = methoxymethyl (MeOCH2 - ), ethoxymethyl, etc., for example, RP(OH)(O)—O-5'-). In some embodiments, the 5' end of the antisense strand of the siRNA includes a 5' vinylphosphonate (VP) modification.
[0099] In the present invention, "pharmaceutically acceptable carrier" may include, but is not limited to, excipients, and / or other components. An "excipient" is a pharmaceutically acceptable solvent, suspending agent, or any other pharmaceutically inert medium for delivering one or more nucleic acids to an animal. Such agents are well known in the art. The compositions of the present invention may additionally contain other auxiliary components conventionally present in pharmaceutical compositions at established usage levels in the art. Thus, for example, the composition may contain additional, compatible pharmaceutically active substances, such as antipruritic agents, astringents, local anesthetics, or anti-inflammatory agents, or may contain additional substances that can be used to physically formulate various dosage forms of the compositions of the present invention, such as preservatives, antioxidants, and stabilizers. However, when added, such substances should not unduly interfere with the biological activity of the components of the compositions of the present invention. The formulations may be sterilized and, if desired, may be mixed with adjuvants that do not deleteriously interact with the nucleic acids of the formulations, such as preservatives, stabilizers, wetting agents, emulsifiers, salts that affect osmotic pressure, or buffers.
[0100] In the present invention, siRNA or siRNA conjugates can be incorporated into a delivery vehicle, such as a liposome or a particle. Typically, as described herein, the siRNA composition is formulated in a manner compatible with the intended method of administration. For example, in specific embodiments, the composition is prepared by at least one of the following methods: spray drying, freeze drying, vacuum drying, evaporation, fluidized bed drying, or a combination of these techniques; or sonication with a lipid, freeze drying, condensation, or other self-assembly.
[0101] In the present invention, the term "liposome" refers to a vesicle composed of amphiphilic lipids and arranged in at least one bilayer (e.g., one or more bilayers). Liposomes include unilamellar and multilamellar vesicles having a membrane formed by a lipophilic material and an aqueous interior. The aqueous portion contains the siRNA or siRNA conjugate. The lipophilic material separates the aqueous interior from an aqueous exterior, which typically does not include the siRNA or siRNA conjugate, but in some instances, may do so. Liposomes are suitable for transferring and delivering active ingredients to the site of action. Because the liposome membrane is structurally similar to biological membranes, when liposomes are administered to a tissue, the liposome bilayer fuses with the bilayer of the cell membrane. As the fusion of the liposome and the cell proceeds, the internal aqueous contents, including the siRNA or siRNA conjugate, are delivered to the cell, where the siRNA or siRNA conjugate can specifically bind to a target RNA and mediate RNAi. In some cases, these liposomes are also specifically targeted, for example, to direct the siRNA or siRNA conjugate to a specific cell type.
[0102] An siRNA formulation can be formulated in combination with another agent, such as another therapeutic agent or an agent that stabilizes the siRNA, such as a protein that complexes with the siRNA to form an iRNP. Still other agents include chelating agents such as EDTA (e.g., to remove divalent cations such as Mg 2+ )), salts, RNase inhibitors (e.g., a broad specificity RNase inhibitor, such as RNAsin), and the like.
[0103] In some embodiments, the siRNA formulation includes another siRNA compound, for example, a second siRNA that mediates RNAi against a second gene or against the same gene. Other formulations can include at least 3, 5, 10, 20, 50, or 100 or more different siRNA species. Such siRNAs can mediate RNAi against a similar number of different genes.
[0104] In some embodiments, the siRNA formulation includes at least one second therapeutic agent (e.g., an agent other than an RNA or a DNA). In some embodiments, the second therapeutic agent comprises a drug for treating nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, obesity, insulin resistance, or other metabolic syndromes.
[0105] The iRNA agents of the present invention can be formulated for pharmaceutical use. Pharmaceutically acceptable compositions include a therapeutically effective amount of one or more of the dsRNA agents of any of the above embodiments, alone or in combination with one or more pharmaceutically acceptable carriers (additives), excipients, and / or diluents.
[0106] The pharmaceutical compositions can be specifically formulated for administration in solid or liquid form, including forms suitable for: (1) oral administration, such as drenches (aqueous or non-aqueous solutions or suspensions), tablets (e.g., tablets targeted for buccal, sublingual, and systemic absorption), boluses, powders, granules, pastes for application to the tongue; (2) parenteral administration, such as by subcutaneous, intramuscular, intravenous, or epidural injection, as, for example, a sterile solution or suspension or a sustained-release formulation; (3) topical administration, such as in the form of a cream, ointment, or a controlled-release patch or spray applied to the skin; (4) intravaginally or intrarectally, such as in the form of a pessary, cream, or foam; (5) sublingually; (6) ocularly; (7) transdermally; or (8) nasally. Delivery using subcutaneous or intravenous methods can be particularly advantageous.
[0107] A composition comprising an iRNA can be delivered to a subject by a variety of routes. Exemplary routes include intravenous, subcutaneous, topical, rectal, anal, vaginal, nasal, pulmonary, and ocular.
[0108] The compositions of the present invention can be administered in a variety of ways, depending on whether local or systemic treatment is desired and on the area to be treated. Administration can be topical (including ocular, vaginal, rectal, intranasal, transdermal), oral, or parenteral. Parenteral administration includes subcutaneous injection, intravenous drip, intravenous injection, intraperitoneal or intramuscular injection, or intrathecal or intraventricular administration.
[0109] The route and site of administration can be selected to enhance targeting. For example, to target muscle cells, intramuscular injection into the muscle of interest would be a logical choice. Pneumocytes can be targeted by administering the iRNA in aerosol form. Vascular endothelial cells can be targeted by coating a balloon catheter with the iRNA and mechanically introducing the DNA.
[0110] The abbreviations or abbreviations used in the present invention are as follows: (invAb) is inverted abasic ribonucleic acid, and VP is vinylphosphonate. BRIEF DESCRIPTION OF THE DRAWINGS
[0111] Figure 1 shows the improvement of NASH in hDGAT2- and Western diet-induced nonalcoholic steatohepatitis by NAFLD activity score x dS319 over 4 weeks.
[0112] Figure 2 shows the improvement of fibrosis in hDGAT2- and Western diet-induced NAFLD by NAFLD activity score x dS319 for 4 weeks. DETAILED DESCRIPTION
[0113] The following examples are provided to illustrate the present invention and are intended to provide a better understanding of the present invention, but are not intended to limit the scope of the present invention. Modifications or variations to the elements of the present invention without departing from the spirit and substance of the present invention are considered to be within the scope of the present invention. Unless otherwise specified, the reagents, kits, and biological materials used in the present invention are commercially available. Kits used in the present invention were used according to the kit instructions unless otherwise specified.
[0114] Example 1: Synthesis of siRNA molecules
[0115] Oligoribonucleotides were synthesized using the phosphoramidite solid-phase synthesis technique. Synthesis was performed on universal controlled pore glass (CPG). All 2'-modified RNA phosphoramidites and auxiliary reagents were commercially available. All phosphoramidites were dissolved in anhydrous acetonitrile and molecular sieves were added. The coupling time was 1.0 min using 5-ethylthio-1H-tetrazole (ETT) as an activator. Phosphorothioate bonds were generated using a 50 mM solution of 3-((dimethylamino-methylene)amino)-3H-1,2,4-dithiazole-3-thione (DDTT) in anhydrous acetonitrile / pyridine (v / v = 1 / 1) with a reaction time of 1.8 min. All sequences were synthesized after the final removal of the DMT group.
[0116] Cleavage and deprotection of oligomers bound to CPG: After solid-phase synthesis is completed, the protecting groups are removed by treatment with acetonitrile containing 20% diethylamine for 30 minutes, without cleaving the oligonucleotide from the CPG. Subsequently, the dried CPG is treated with concentrated aqueous ammonia at 40 degrees Celsius for 18 hours. After centrifugation, the supernatant is transferred to a new tube and the CPG is washed with aqueous ammonia. The combined solution is concentrated to obtain a solid mixture.
[0117] Purification of single-stranded oligoribonucleotides: Oligomers were purified by HPLC using a NanoQ anion exchange column. Buffer A consisted of 10 mM sodium perchlorate, 20 mM Tris, 1 mM EDTA, pH 7.4, and 20% acetonitrile, and buffer B consisted of 500 mM sodium perchlorate, 20 mM Tris, 1 mM EDTA, pH 7.4, and 20% acetonitrile. The desired product was isolated and desalted using a reversed-phase C18 column.
[0118] Annealing of single-stranded oligoribonucleotides to produce siRNA: Prepare the single-stranded oligoribonucleotides to be annealed at a concentration of 200 μM using sterile RNase-free H2O (RNA hydrolase-free). Set up the annealing reaction as follows: Place 10 nmol of the mixture in a 95°C water bath for 10 minutes (amounts ≥ 100 nmol require 20 minutes at high temperature). Immediately place the mixture in a 60°C water bath and allow to cool naturally. Do not store the annealed solution at high temperatures. Complementary strands are formed by combining equimolar amounts of the single-stranded oligoribonucleotide solutions.
[0119] Example 2: In vitro inhibitory activity test of the test substance on the target gene DGAT2
[0120] 1. Materials and Methods
[0121] 1.1 Materials
[0122] 1.1.1 Test compounds
[0123] The structures of the test compounds are shown in Table 2: 20 μM stock solutions were prepared in PBS.
[0124] 1.1.2 Cell lines
[0125] Huh7 cells. Huh7 cells were cultured in Dulbecco's Modified Eagle's Medium (Gibco No. 11965-092) supplemented with 10% fetal bovine serum (FBS, ExCell Bio Product No. FSP500), 1% glutamine (GlutaMAX, Gibco Product No. 35050061), 1% NEAA (Gibco Product No. 11140050), and 1% penicillin-streptomycin (HyClone Product No. SV30010).
[0126] 1.1.3 Main instruments
[0127] The main instruments used in this experiment include a fluorescence qPCR instrument (Quanstudio 7flex), a centrifuge (Beckman Allegra-X15R Centrifuge), and a cell counter (Countstar Rigel2).
[0128] 1.1.4 Main reagents and consumables
[0129] The main reagents used in this experiment include Lipofectamine TM iRNAiMAX Transfection Reagent (INVITROGEN, Cat. No. 13778150), FastStart Universal Probe Master (Roche, Cat. No. 04914058001), RNA Extraction Kit (Qiagen, Cat. No. 74182), FastKing cDNA First-Strand Synthesis Kit (TianGen, Cat. No. KR116-02), 96-well plates (Costar 3599). TaqMan Gene Expression Assays for GAPDH (Thermo, Cat. No. Hs02786624_g1) and DGAT2 (Thermo, Cat. No. Hs01045913_m1).
[0130] 2. Experimental Methods
[0131] 2.1 Compound transfection and plating
[0132] Huh7 cells (2×10⁴ cells / well) were seeded into 96-well plates and transfected with siRNA using RNAiMAX. Two siRNA concentrations (10 nM and 0.5 nM) were tested. The cells were incubated overnight at 37°C in a 5% CO₂ incubator. The assay was performed in duplicate. A control group containing RNAiMAX and no compound was also established.
[0133] 2.2 RNA extraction and reverse transcription
[0134] 24 hours after transfection, the culture medium was removed and the cells were collected for RNA extraction. Total RNA was extracted using QIAGEN-74182 RT Kit and cDNA was synthesized using the FastKing RT Kit (with gDNase) (Tiangen-KR116-02) according to the manufacturer's instructions.
[0135] 2.3 Detection of target gene mRNA expression levels by qPCR
[0136] Target cDNA will be detected by qPCR, along with GAPDH cDNA as an internal control. 8 μL of the prepared PCR reaction solution and 2 μL of sample cDNA will be added to each 384-well plate. The qPCR reaction program is as follows: heat at 95°C for 10 minutes, then cycle at 95°C for 15 seconds, followed by 60°C for 1 minute, for a total of 40 cycles.
[0137] 3 Data Analysis
[0138] The target gene mRNA expression level for each sample was calculated using the ΔΔCt relative quantification method. The relative expression of the target gene was expressed as 2-ΔΔCT.
[0139] The calculation formula is as follows:
[0140] ΔCT = average Ct value of target gene - average Ct value of reference gene
[0141] ΔΔCT = ΔCT (drug-treated group) - ΔCT (RNAiMAX control group)
[0142] Relative expression of target gene DGAT2 = 2-ΔΔCT
[0143] DGAT2 inhibition rate % = (1-measured value of the drug-treated group / average value of the RNAiMAX control group) * 100
[0144] GraphPad Prism software was used for graphical analysis, and the inhibition rate results were expressed as mean ± SD.
[0145] Test results:
[0146] Table 3.1 In vitro inhibitory activity test of the test substance on the target gene DGAT2
[0147] Table 3.2 In vitro inhibitory activity test of the test substance on the target gene DGAT2
[0148] Table 3.3 In vitro inhibitory activity test of the test substance on the target gene DGAT2
[0149] in conclusion:
[0150] The double-stranded RNA compound provided by the present application can significantly inhibit the level of DGAT2 mRNA in cells.
[0151] Example 3: Inhibitory effect of the test substance on the target gene DGAT2 in primary human hepatocytes (PHH)
[0152] Test compound:
[0153] Prepare a 100 μM / 200 μM stock solution in PBS.
[0154] cell:
[0155] Primary human hepatocytes (PHH): PHH were revived and cultured in InvitroGRO CP medium (BIOIVT Catalog No. S0331) containing 10% fetal bovine serum (FBS, Gibco Catalog No. 10091148) and 1% penicillin-streptomycin (PS, HyClone Catalog No. SV30010).
[0156] Main reagents and consumables:
[0157] The main reagents used in this experiment include FastStart Universal Probe Master (ROCHE Product No. 04914058001), RNA extraction kit (Qiagen Product No. 74182), HiScript III RT SuperMix for qPCR (+gDNA wiper) (Vazyme Product No. R323-01), 96-well plate (Costar Product No. 3599), GAPDH Gene Expression Assays (60×) (Thermo Catalog No. Hs02786624_g1), DGAT2 Gene Expression Assays (60×) (Thermo catalog number Hs01045913_m1).
[0158] Experimental methods:
[0159] Compound ad libitum uptake plating
[0160] PHH (5.4×10⁴ cells / well) were seeded into 96-well plates and siRNA was added to the cells simultaneously with plating. Compounds were allowed to enter the cells through free uptake. The siRNA assay was performed at nine concentrations (100 nM, 20 nM, 4 nM, 0.8 nM, 0.16 nM, 0.032 nM, and 0.0064 nM) in duplicate. A control group containing no compound and PBS was also established. The cells were then incubated at 37°C in a 5% CO₂ incubator.
[0161] RNA extraction and reverse transcription
[0162] After 48 hours, the culture medium was removed and the cells were collected for RNA extraction. Total RNA was extracted using QIAGEN 96 Kit (QIAGEN-74182), and cDNA was synthesized using HiScript III RT SuperMix for qPCR (+gDNA wiper) (Vazyme Product No. R323-01) according to the manufacturer's instructions.
[0163] qPCR detection of target gene mRNA expression levels
[0164] Target gene cDNA was detected by qPCR, along with the internal reference gene GAPDH cDNA. 8 μL of the prepared PCR reaction solution and 2 μL of sample cDNA were added to a 384-well plate. The qPCR reaction program was as follows: 50°C for 2 minutes, 95°C for 10 minutes, followed by cycling at 95°C for 15 seconds, followed by 60°C for 1 minute, for a total of 40 cycles.
[0165] Experimental results:
[0166] See Table 4.1 and Table 4.2.
[0167] Table 4.1 Inhibition rate of the test substances on target gene DGAT2 mRNA in primary human hepatocytes
[0168] Table 4.2 IC50 inhibition rate of dS319 on target gene DGAT2 mRNA in primary human hepatocytes
[0169] Example 4: Evaluation of the Inhibitory Activity of siRNA Compounds on the Target Gene DGAT2 in Wild Mice
[0170] animal
[0171] Male C57BL / 6 mice, 6 weeks old, were specific pathogen-free and housed in individually ventilated cages. Animals were acclimated for 7 days prior to the experiment.
[0172] Solvents and test compounds
[0173] Solvent: Phosphate buffered saline, filtered on the day of administration for preparation.
[0174] Reagents and consumables
[0175] The main reagents and consumables are shown in the table below.
[0176] In vivo experiments
[0177] Animal dosing and sample collection methods The in vivo experimental design is shown in the table below.
[0178] Table 5 Evaluation of the in vivo inhibitory activity of siRNA compounds against the target gene DGAT2 in wild-type mice after 7 and 28 days of administration
[0179] Example 5: Activity evaluation of the test compound in a mouse model of DGAT2 plasmid tail vein hyperbaric injection
[0180] Materials and Methods
[0181] Material
[0182] animal
[0183] BALB / c mice, female, 6-7 weeks old.
[0184] DGAT2 plasmid DNA
[0185] The pcDNA-DGAT2 plasmid was diluted with normal saline at a concentration of 2 μg / μL for later use.
[0186] Reagents and consumables
[0187] The main reagents and consumables are shown in the table below.
[0188] Experimental methods
[0189] In vivo experiments
[0190] The protocol for DGAT2 plasmid DNA tail vein high-pressure injection, administration, and sample collection methods are described below.
[0191] Compound treatment: The day of administration is defined as day 0, the day before is day -1, the day after is day 1, etc. On day 0, mice are subcutaneously injected with the solvent or the test compound at a volume of 5 mL / kg, with a dosage of 3 mpk.
[0192] Mice were injected with DGAT2 plasmid DNA solution via tail vein hyperbaric injection: On day 4 or 14, plasmid DNA was prepared in normal saline and stored at 4°C until use. All mice were injected with 10 μg of plasmid DNA solution (8% of their body weight) via the tail vein over 5 seconds (injection volume (mL) = mouse weight (g) x 8%).
[0193] Experimental endpoint and liver sample collection: On day 5 or 15, 24 hours after high-pressure tail vein injection of DGAT2 plasmid, all mice were euthanized by CO2 inhalation. After euthanasia, blood was collected from the heart and liver samples were collected. Two 70 mg portions of liver tissue were immersed in After incubation at 4°C overnight, the supernatant was discarded and transferred to a -80°C refrigerator for mRNA detection.
[0194] Sample analysis
[0195] Detection of DGAT2 gene expression in mouse liver by quantitative PCR
[0196] RNA from the liver was extracted using Trizol. The method is briefly described as follows: 50-70 mg of liver tissue and 1.2 mL of Trizol were homogenized using a Qiagen Tissue Lyser II at 26 Hz for 2 minutes. Lysis was performed at room temperature for 5 minutes. 1 mL of the supernatant was collected, 200 μL of chloroform was added, and the mixture was vigorously shaken for 15 seconds. After standing for 3 minutes, the supernatant was centrifuged and collected. An equal volume of isopropanol was added and the mixture was precipitated overnight at -20°C. The mixture was washed twice with 70% ethanol and dissolved in RNase-free water. The RNA sample concentration was determined using a Nanodrop ONE and diluted to 400 ng / μL with RNase-free water for reverse transcription.
[0197] The reverse transcription experimental steps refer to the instructions of the FastKing cDNA First Strand Synthesis Kit (Genomic Removal). Briefly described as follows: Prepare the gDNA removal mixture according to Table 6. Add the mixture (5 μL / sample) and 400 ng / μL RNA sample to a 96-well PCR reaction plate, incubate at 42°C for 3 minutes, and cool on ice. Prepare the reverse transcription mixture according to Table 7, add the reverse transcription mixture (10 μL / sample) and the DNA removal product from the previous step to a 96-well PCR reaction plate for reverse transcription. Reaction conditions: 42°C, 15 minutes; 95°C, 3 minutes. Store the cDNA at 4°C for further analysis.
[0198] Table 6 gDNA-removal reaction components
[0199] Table 7 RT-PCR reaction components
[0200] The quantitative PCR method for detecting DGAT2 and NEO gene expression in mouse liver is briefly described as follows: As shown in Tables 8 and 9, a qPCR reaction mixture was prepared, and 2 μL of the cDNA sample diluted fourfold with RNase-free water was added to the mixture. PCR reactions were performed under the following conditions: 95°C for 10 minutes, followed by 40 cycles of 95°C for 15 seconds and 60°C for 1 minute.
[0201] Table 8 qPCR reaction components (DGAT2)
[0202] Table 9 qPCR reaction components (NEO)
[0203] The ΔΔCt method was used to analyze the expression of the target gene in each test sample. This method measures the Ct difference (ΔCt) between the target gene (DGAT2) and the reference gene (Neo), and compares the ΔCt values of the compound-treated samples with those of the control group.
[0204] The formula is:
[0205] ΔCt = average Ct value of target gene - average Ct value of reference gene.
[0206] ΔΔCt = ΔCt of compound-treated samples - average ΔCt of the control group.
[0207] Gene expression level = 2 -ΔΔCT
[0208] Data analysis: Data are expressed as mean ± standard error of each mouse sample group, n = 4 or 5 unless otherwise specified. Statistical analysis was performed using Student's t test.
[0209] Table 10.1 Evaluation of in vivo inhibitory activity of siRNA compounds against target gene DGAT2 in hDGAT2 HDI mouse model after 5 days of administration
[0210] Table 10.2 Evaluation of in vivo inhibitory activity of siRNA compounds against target gene DGAT2 in hDGAT2 HDI mouse model after 15 days of administration
[0211] Example 6: Inhibitory activity test of the double-stranded RNA conjugate of the present invention on the target gene DGAT2 in mice
[0212] Animals: Male C57BL / 6 mice, 6 weeks old, specific pathogen-free. Animals were acclimated to the environment for 7 days before the experiment.
[0213] Solvent: phosphate buffered saline (PBS).
[0214] Reagents and consumables: See the table below.
[0215] In vivo experiments: Animal dosing and sample collection methods The in vivo experimental design is shown in the table below.
[0216] Definition of experimental days: The day on which the mice were first dosed was defined as day 0 of the experiment, the day before that was day -1, the day after that was day 1, and so on.
[0217] All mice were administered a single SC dose of PBS, control compound, or test compound on day 0. On day 7, mice were bled submandibularly for plasma collection, then euthanized and cardiac blood was collected for later use. Liver samples were collected for targeted liver mRNA level analysis.
[0218] Sample detection and analysis: RT-PCR was used to quantitatively detect the target mRNA levels in liver tissue.
[0219] The expression of the target gene in each test sample was analyzed using the ΔΔCt method. This method measures the Ct difference (ΔCt) between the target gene (DGAT2) and the reference gene (GAPDH), and compares the ΔCt values of the compound-treated samples with those of the control group.
[0220] The formula is:
[0221] ΔCt = average Ct value of target gene - average Ct value of reference gene.
[0222] ΔΔCt = ΔCt of compound-treated samples - average ΔCt of the control group.
[0223] Gene expression level = 2 -ΔΔCT
[0224] Data analysis: Data are presented as mean ± standard error of each mouse group, n = 4 unless otherwise specified. Statistical analysis was performed using Student's t test.
[0225] Experimental results: See Table 11.
[0226] Table 11 Test results of the inhibitory activity of double-stranded RNA conjugates on the target gene DGAT2 in wild mice
[0227] Conclusion: The double-stranded RNA conjugate of the present invention effectively inhibits the expression of the target gene DGAT2.
[0228] Example 7: Inhibitory activity test of double-stranded RNA conjugate against target gene DGAT2 in mice injected with human DGAT2 plasmid by high pressure tail vein injection (HDI)
[0229] Animals: BALB / c female mice, 6-7 weeks old.
[0230] DGAT2 plasmid DNA: pcDNA-DGAT2 plasmid, concentration is 2 μg / μL, diluted with normal saline for later use.
[0231] Reagents and consumables: see the table below
[0232] Experimental methods:
[0233] The in vivo experimental design for DGAT2 plasmid DNA tail vein high-pressure injection, drug administration and sample collection methods are shown in the table below.
[0234] Compound treatment: The day mice were dosed was defined as day 0, the day before was day -1, the day after was day 1, and so on. On day 0, mice were subcutaneously injected with the solvent or test compound at a volume of 5 mL / kg. Detailed information is shown in Table 5.
[0235] Mice were injected with DGAT2 plasmid DNA solution via tail vein hyperbaric injection: On day 14, plasmid DNA was prepared in normal saline and stored at 4°C until use. All mice were injected with 10 μg of plasmid DNA solution (8% of their body weight) via the tail vein over 5 seconds (injection volume (mL) = mouse weight (g) x 8%).
[0236] Experimental endpoint and liver sample collection: On day 15, 24 hours after high-pressure tail vein injection of DGAT2 plasmid, all mice were euthanized by CO2 inhalation. After euthanasia, blood was collected from the heart and liver samples were collected. Two 70 mg portions of liver tissue were immersed in After incubation at 4°C overnight, the supernatant was discarded and transferred to a -80°C refrigerator for mRNA detection.
[0237] Quantitative PCR detection of DGAT2 gene expression in mouse liver:
[0238] RNA was extracted from the liver using Trizol. RNA sample concentration was determined using a Nanodrop ONE (ultra-micro UV-visible spectrophotometer) and diluted to 400 ng / μL with RNase-free water for reverse transcription. The expression levels of DGAT2 and NEO genes in mouse liver were determined by quantitative PCR.
[0239] Experimental results: see Table 6.
[0240] Table 12 Test results of the inhibitory activity of double-stranded RNA conjugates on the target gene DGAT2 in mice
[0241] Conclusion: The double-stranded RNA conjugate of the present invention effectively inhibits the expression of the target gene DGAT2.
[0242] Example 8: Inhibitory activity test of double-stranded RNA conjugate against target gene DGAT2 in mice injected with human DGAT2 plasmid by high pressure tail vein injection (HDI)
[0243] Animals: BALB / c female mice, 6-7 weeks old.
[0244] DGAT2 plasmid DNA: pcDNA-DGAT2 plasmid, concentration is 2 μg / μL, diluted with normal saline for later use.
[0245] Reagents and consumables: See the table below.
[0246] Experimental methods: DGAT2 plasmid DNA was injected into the tail vein by high pressure. The in vivo experimental design of the drug administration and sample collection methods are shown in the table below.
[0247] Compound treatment: The day of administration is defined as day 0, the day before is day -1, the day after is day 1, etc. On day 0, mice are subcutaneously injected with the solvent or the test compound at a volume of 5 mL / kg.
[0248] Mice were injected with DGAT2 plasmid DNA solution via tail vein hyperbaric injection: On day 14, plasmid DNA was prepared in normal saline and stored at 4°C until use. All mice were injected with 10 μg of plasmid DNA solution (8% of their body weight) via the tail vein over 5 seconds (injection volume (mL) = mouse weight (g) x 8%).
[0249] Experimental endpoint and liver sample collection: On day 15, 24 hours after high-pressure tail vein injection of DGAT2 plasmid, all mice were euthanized by CO2 inhalation. After euthanasia, blood was collected from the heart and liver samples were collected. Two 70 mg portions of liver tissue were immersed in After incubation at 4°C overnight, the supernatant was discarded and transferred to a -80°C refrigerator for mRNA detection.
[0250] Quantitative PCR was used to detect DGAT2 gene expression in mouse livers. Liver RNA was extracted using Trizol. RNA concentration was determined using a Nanodrop ONE (ultra-micro-volume UV-visible spectrophotometer) and diluted to 400 ng / μL with RNase-free water for reverse transcription. Quantitative PCR was then used to detect DGAT2 and NEO gene expression in mouse livers.
[0251] Experimental results: See Table 13.
[0252] Table 13 Test results of the inhibitory activity of double-stranded RNA conjugates on the target gene DGAT2 in mice
[0253] Conclusion: The double-stranded RNA conjugate of the present application effectively inhibited the expression of the target gene DGAT2.
[0254] Example 9: Improvement of Western diet-induced non-alcoholic steatohepatitis in human DGAT2 mice by double-stranded RNA conjugates Materials and methods
[0255] B6-hDGAT2-TG target humanized mice and a nonalcoholic steatohepatitis model were provided by Jicui Pharmaceuticals. Subcutaneous administration and a Western diet were initiated on D0, with a second injection given on D29. The duration of efficacy was 8 weeks. One group of four mice was sacrificed at the end of the 4-week endpoint, while another group of four mice was sacrificed at the 8-week endpoint.
[0256] Plasma was collected weekly to detect TG, Chol, HDL-C, LDL-C, ALT, and AST levels. At the endpoint, the liver was harvested for HE staining and NASH scoring.
[0257] The test results are shown in Tables 14, 15 and Figures 1 and 2.
[0258] Table 14 dS319 improves NASH and fibrosis at 4 weeks in hDGAT2- and Western diet-induced nonalcoholic steatohepatitis Note: Data are expressed as mean ± SEM, n = 8, Vs G2, *: P < 0.05; **: P < 0.01; ***: P < 0.001; ****: P < 0.0001
[0259] Table 15 dS319 improves NASH and fibrosis at 8 weeks in hDGAT2- and Western diet-induced nonalcoholic steatohepatitis
[0260] Example 10: Results of the Inhibitory Activity Test of Double-stranded RNA Conjugates on the Target Gene DGAT2 in Eluted Cynomolgus Monkeys
[0261] The in vivo experimental design of subcutaneous injection, drug administration and sample collection methods of elution monkeys is shown in the table below.
[0262] The day of administration of the washout monkey was defined as day 1 of the experiment, the day before that was day 0, the day after that was day 2, and so on. There were two monkeys in each group. Groups 1 and 2 were injected with 4 mg / kg of the drug (0.5 mL / kg) with the solvent or the Yangshen compound on days 1, 4, 8, 15, 22, 29, 36, 43, 50, and 57. Groups 3 to 7 were injected subcutaneously with the test compound on days 1 and 29 at a volume of 0.5 mL / kg. Details are shown in the table below.
[0263] Liver samples were collected at 0 day (0 hours) before SC administration, and on the 7th, 15th, 28th, 57th, and 99th days after administration. Sampling method: Animals need to fast for 12-16 hours before sampling. Liver biopsy tissue collection: The collection process will be performed and recorded according to the research institution's SOP. Use B-ultrasound to determine the location of the liver, generally focusing on the right liver, avoiding the gallbladder and major blood vessels. Insert the biopsy gun under the guidance of the B-ultrasound probe. Guided by the image on the B-ultrasound screen, the gun will enter the liver and perform puncture and sampling away from the gallbladder and major blood vessels. After the biopsy, the biopsy gun will be withdrawn and the sample will be collected. The obtained sample is immediately immersed in The cells were placed in PBS at 4°C overnight, and then the residual liquid was aspirated and stored at -80°C or below until shipped and tested under dry ice.
[0264] Quantitative PCR detection of DGAT2 gene expression in monkey liver:
[0265] Trizol was homogenized using a Qiagen Tissue Lyser II at 26 Hz for 2 minutes. Lysis was performed at room temperature for 5 minutes. 1 mL of supernatant was collected, 200 μL of chloroform was added, and the mixture was shaken for 15 seconds. After standing for 3 minutes, the supernatant was collected by centrifugation. An equal volume of isopropanol was added and the mixture was precipitated overnight at -20°C. The mixture was washed twice with 70% ethanol and dissolved in RNase-free water. The RNA sample concentration was determined using a Nanodrop ONE and diluted to 200 ng / μL with RNase-free water for reverse transcription.
[0266] Reverse transcription experimental steps reference III RT SuperMix for qPCR (+gDNA wiper) instructions. Briefly, prepare the gDNA removal mixture according to the table below. Add a mixture of 4× gDNA wiper mix and RNase-Free ddH2O (11 μL / sample) and 1000 ng of RNA sample (5 μL of RNA sample at a concentration of 200 ng / μL) to a 96-well PCR reaction plate, incubate at 42°C for 2 minutes, and cool on ice. Add 4 μL of 5× HiScript III qRT SuperMix and the DNA removal product from the previous step to a 96-well PCR reaction plate and perform reverse transcription. Reaction conditions: 37°C for 15 minutes; 85°C for 5 seconds. Store cDNA at 4°C for further analysis.
[0267] gDNA-removal reaction components table
[0268] The quantitative PCR method for detecting DGAT2 and GAPDH gene expression in monkey liver is briefly described as follows: Prepare the qPCR reaction mixture as shown in the table below, add 2 μL of the cDNA sample diluted 2x with RNase-free water, and perform the PCR reaction. Reaction conditions: 95°C for 10 minutes, followed by 40 cycles of 95°C for 15 seconds and 60°C for 1 minute.
[0269] qPCR reaction components table (DGAT2)
[0270] Experimental results: See Table 16.
[0271] Table 16 Test results of the inhibitory activity of double-stranded RNA conjugates on the target gene DGAT2 in eluted cynomolgus monkeys
[0272] All values were normalized to the group mean on day 0.
[0273] Example 11: Inhibitory Activity of dS319 Against the Target Gene DGAT2 in Cynomolgus Monkeys. In vivo Experiment: Subcutaneous Injection in the eluted monkeys. Dosing and Sample Collection Methods. The in vivo experimental design is shown in the table below. The day of dosing in the eluted monkeys was defined as Day 1. The day before was Day 0, the day after was Day 2, and so on. Each group consisted of two monkeys. On Days 1 and 29, the monkeys were subcutaneously injected with either the vehicle or the test compound at a volume of 0.5 mL / kg.
[0274] Liver samples were collected on day 0 (0 hours) before SC administration, and on days 7, 29, 56, and 99 after administration. Sampling method: Animals were fasted for 12-16 hours before sampling. Liver biopsy tissue collection: The collection process was performed and recorded according to the research institution's SOP.
[0275] Experimental results: See Table 17.
[0276] Table 17 Test results of the inhibitory activity of double-stranded RNA conjugates on the target gene DGAT2 in eluted cynomolgus monkeys
[0277] Conclusion: The double-stranded RNA conjugate dS319 has a long-term inhibitory efficiency on the target gene DGAT2 in the washed crab, and is superior to the clinical molecule in terms of dosage and injection frequency.
Claims
1. A siRNA, comprising a sense strand and an antisense strand, wherein at least a portion of the sense strand and at least a portion of the antisense strand are reverse complementary to each other and form a double-stranded region, wherein: The positive strand comprises 17 to 22 consecutive bases in a sequence as shown in any one of SEQ ID NOs: 1-96; further, comprises 20 consecutive bases in a sequence as shown in any one of SEQ ID NOs: 1-96; further, comprises a base sequence as shown in any one of SEQ ID NOs: 1-96.
2. An siRNA, comprising a sense strand and an antisense strand, wherein at least a portion of the sense strand and at least a portion of the antisense strand are reverse complementary to each other and form a double-stranded region, wherein: The antisense strand comprises 17 to 22 consecutive bases in a sequence as shown in any one of SEQ ID NOs: 97-192; further, comprises 20 consecutive bases in a sequence as shown in any one of SEQ ID NOs: 97-192; further, comprises a base sequence as shown in any one of SEQ ID NOs: 97-192 and 194-199.
3. The siRNA according to claim 1 or 2, wherein a) the sense strand comprises 17 to 22 (further 20 consecutive) bases of a sequence as shown in SEQ ID NO: 77 or SEQ ID NO: 201, and the antisense strand comprises 17 to 22 (further 20 consecutive) bases of a sequence as shown in SEQ ID NO: 173, 194, 195 or 200; or b) the sense strand comprises 17 to 22 (further 20) consecutive bases of the sequence shown in SEQ ID NO: 17, and the antisense strand comprises 17 to 22 (further 20) consecutive bases of the sequence shown in SEQ ID NO: 113, 196, or 197; or c) the sense strand comprises 17 to 22 (further 20 consecutive) bases of the sequence shown in SEQ ID NO:80, and the antisense strand comprises 17 to 22 (further 20 consecutive) bases of the sequence shown in SEQ ID NO:176, 198 or 199.
4. The siRNA according to claim 3, wherein a) the sense strand comprises the sequence shown in SEQ ID NO:77 or SEQ ID NO:201, and the antisense strand comprises the sequence shown in SEQ ID NO:194, SEQ ID NO:195 or SEQ ID NO:200; or b) the sense strand comprises the sequence shown in SEQ ID NO: 17, and the antisense strand comprises the sequence shown in SEQ ID NO: 196 or SEQ ID NO: 197; or c) the sense strand comprises the sequence shown in SEQ ID NO:80, and the antisense strand comprises the sequence shown in SEQ ID NO:198 or SEQ ID NO:
199.
5. The siRNA according to any one of claims 1 to 4, wherein The siRNA comprises one or more modified nucleotides; further, all nucleotides are modified nucleotides.
6. The siRNA according to claim 5, wherein The modified nucleotides are selected from 2'-methoxy modified nucleotides or 2'-fluoro modified nucleotides.
7. The siRNA according to any one of claims 1 to 6, wherein The siRNA comprises an abasic nucleotide; optionally, the abasic nucleotide is an inverted abasic nucleotide.
8. The siRNA according to claim 7, wherein The 5' end of the sense strand of the siRNA comprises the abasic nucleotide.
9. The siRNA according to any one of claims 1 to 8, wherein The siRNA includes one or more modified internucleoside linkages.
10. The siRNA according to claim 9, wherein The modified internucleoside linkages are phosphorothioates.
11. The siRNA according to any one of claims 1 to 10, wherein The siRNA includes a 5' terminal phosphate or a phosphate analog modification; further, the 5' end of the antisense strand of the siRNA includes a 5' terminal phosphate or a phosphate analog modification.
12. The siRNA of claims 1-11, wherein The phosphate analog modification is a vinylphosphonate (VP) modification.
13. The siRNA according to claim 1 or 2, wherein The siRNA is selected from dS004-dS099.
14. The siRNA according to claim 1 or 2, wherein The siRNA is selected from any one of the siRNAs shown in Table 2; further, selected from dS004, dS005, dS006, dS007, dS008, dS009, dS010, dS011, dS012, dS013, dS014, dS015, dS016, dS017, dS018, dS019, dS020, dS021, dS022, dS023, dS024, dS025, dS026 , dS027, dS028, dS029, dS030, dS031, dS032, dS033, dS034, dS035, dS036, dS037, dS038, dS039, dS04 0. dS041, dS042, dS043, dS044, dS045, dS046, dS047, dS048, dS049, dS050, dS051, dS052, dS053, dS0 54. dS055, dS056, dS057, dS058, dS059, dS060, dS061, dS062, dS063, dS064, dS065, dS066, dS067, dS 068, dS069, dS070, dS071, dS072, dS073, dS074, dS075, dS076, dS077, dS078, dS079, dS080, dS081, d dS090, dS091, dS092, dS093, dS094, dS095, dS096, dS097, dS098, dS099, dS279, dS280, dS281, dS282, dS283, dS284, dS285, dS286, dS287, or dS288.
15. A siRNA conjugate, comprising the siRNA according to any one of claims 1 to 14 and a ligand group, wherein the ligand group is conjugated to the siRNA, the ligand group comprises 1, 2, 3 or 4 GalNAc groups, and the number of the ligand groups is 1, 2, 3, 4, 5, 6 or 7.
16. The siRNA conjugate according to claim 15, wherein The ligand group is conjugated to the 3' end of the sense strand.
17. The siRNA conjugate according to claim 15 or 16, wherein The siRNA is selected from any one of the siRNA conjugates shown in Table 2; further selected from dS301, dS302, dS303, dS304, dS305, dS306, dS307, dS316, dS319 or dS324.
18. The siRNA conjugate according to any one of claims 15 to 17, wherein The ligand group is selected from NAG37 or L96.
19. A pharmaceutical composition comprising the siRNA according to any one of claims 1 to 14 or the siRNA conjugate according to any one of claims 15 to 18, and a pharmaceutically acceptable carrier.
20. Use of the siRNA according to any one of claims 1 to 14 or the siRNA conjugate according to any one of claims 15 to 18 in the preparation of a drug for treating a disease associated with DGAT2 expression; further, the disease associated with DGAT2 expression is a lipid metabolism disease; further, the disease associated with DGAT2 expression is non-alcoholic fatty liver disease and non-alcoholic steatohepatitis.
Citation Information
Patent Citations
Modulators of diacyglycerol acyltransferase 2 (DGAT2)
CN109477106A
Products and compositions
CN110520531A
Oligonucleotides for DGAT2 modulation
US20220228141A1
Compositions and methods for the treatment of metabolic syndrome
WO2022031850A2
Treatment of cardiovascular disease
WO2022136466A1
Cited By
Double‑stranded RNA composition for modulating DGAT2 expression, conjugate thereof, pharmaceutical composition comprising same, and use thereof
WO2026130386A1
